In accordance with provisions of the merger agreement, the company has elected to terminate the merger agreement with StemTroniX, Inc., a Texas corporation, previously announced by Power3 on February 11, 2010, and temporarily restrained from completing due to issues solely related to StemTroniX. Notwithstanding this, the company has been assured full assignment of the recently filed provisional patent application entitled, "Stem cell protein biomarkers and their use in monitoring stem cells and their products for stem cell therapy." Power3 also announced its intention to acquire additional stem cell companies, technologies and intellectual property.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.